- Home
- WFC vs NVO Comparison
WFC vs NVO Comparison
Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFC
- NVO
- Stock Information
- Founded
- WFC 1852
- NVO 1923
- Country
- WFC United States
- NVO Denmark
- Employees
- WFC N/A
- NVO N/A
- Industry
- WFC Major Banks
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WFC Finance
- NVO Health Care
- Exchange
- WFC Nasdaq
- NVO Nasdaq
- Market Cap
- WFC 254.4B
- NVO 278.0B
- IPO Year
- WFC N/A
- NVO N/A
- Fundamental
- Price
- WFC $82.20
- NVO $56.47
- Analyst Decision
- WFC Buy
- NVO Buy
- Analyst Count
- WFC 16
- NVO 7
- Target Price
- WFC $81.10
- NVO $98.00
- AVG Volume (30 Days)
- WFC 13.4M
- NVO 19.2M
- Earning Date
- WFC 10-10-2025
- NVO 08-06-2025
- Dividend Yield
- WFC 2.19%
- NVO 2.18%
- EPS Growth
- WFC 19.49
- NVO 24.25
- EPS
- WFC 5.82
- NVO 3.93
- Revenue
- WFC $77,618,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- WFC $7.81
- NVO $10.01
- Revenue Next Year
- WFC $4.68
- NVO $9.93
- P/E Ratio
- WFC $14.11
- NVO $14.29
- Revenue Growth
- WFC N/A
- NVO 20.91
- 52 Week Low
- WFC $50.22
- NVO $45.05
- 52 Week High
- WFC $84.83
- NVO $139.74
- Technical
- Relative Strength Index (RSI)
- WFC 59.73
- NVO 50.81
- Support Level
- WFC $76.59
- NVO $54.60
- Resistance Level
- WFC $83.21
- NVO $56.76
- Average True Range (ATR)
- WFC 1.54
- NVO 1.15
- MACD
- WFC 0.51
- NVO 1.10
- Stochastic Oscillator
- WFC 81.27
- NVO 79.13
About WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.